1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)

Scope of the Report

The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)” provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Pfizer Inc, Merck & Co, Allergan Inc and Alcon (Division of Novartis) are profiled in the report.?

Countries Coverage

- The US
- Japan

Company Coverage

- Pfizer Inc,
- Merck & Co,
- Allergan Inc and
- Alcon (Division of Novartis)

Executive Summary

Glaucoma, the second most common cause of blindness worldwide is generally characterized by relatively high intraocular pressure (IOP) as a result of impaired drainage of fluid, known as aqueous humor, from the eye. Currently approved treatments for glaucoma include a number of pharmaceutical drugs, laser therapies and surgical procedures. Glaucoma treatment forms a significant portion of the overall eye care market.
The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years.

The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug.

Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed.

Table Of Contents

Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)
1. Executive Summary

2. Glaucoma: A Major Cause of Vision Loss

2.1 Overview
2.2 Types of Glaucoma
2.3 Prevention and Treatment of Glaucoma

3. Global Eye Care Market: An Analysis

3.1 Global Eye Care Market: Sizing and Growth
3.2 Global Eye Care Market Segmentation
3.3 Eye Care Surgical Market
3.4 Ophthalmic Pharmaceuticals Market
3.5 Vision Care Market

4. Global Glaucoma Treatment Market: An Analysis

4.1 Global Glaucoma Treatment Market: Sizing and Growth
4.2 Global Glaucoma Treatment Market: Share by Type of Drugs
4.3 Glaucoma Devices Market

5. Regional Analysis: Glaucoma Treatment Market

5.1 The US Glaucoma Treatment Market
5.2 Japan Glaucoma Treatment Market

6. Market Dynamics: Global Glaucoma Treatment Market

6.1 Growth Drivers: Glaucoma Treatment Market

6.1.1 Rising Ageing Population
6.1.2 Rising Healthcare Expenditures
6.1.3 New Glaucoma Drug Delivery Devices

6.2 Key Issues: Glaucoma Treatment Market

6.2.1 Strict Regulation and Marketing Approval
6.2.2 Long Product Development Process
6.2.3 Side Effects of Glaucoma Medications

6.3 Market Trends: Glaucoma Treatment Market

6.3.1 Medicare Coverage of Glaucoma Patients
6.3.2 New Laser Technologies
6.3.3 Demand for Combination Glaucoma Drugs

7. Competitive Landscape: Glaucoma Treatment Market

8. Company Profiles: Glaucoma Treatment Market

8.1 Pfizer Inc.
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 Business Strategies

8.2 Merck and Co., Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategies

8.3 Allergan Inc.
8.3.1 Business Description
8.3.2 Financial Overview
8.3.3 Business Strategies

8.4 Alcon (Division of Novartis)
8.4.1 Business Description
8.4.2 Financial Overview
8.4.3 Business Strategies

List of Figures

Figure 1: Diagram of the Structure of the Eye (left) and Damage from Glaucoma (Right)
Figure 2: Global Eye Care Market Size in US$ Billion, 2013-2018F
Figure 3: Global Eye Care Market Segmentation in %, 2013
Figure 4: Breakup of Global Eye Surgical Market in US$ Billion, 2013
Figure 5: Breakup of Global Ophthalmic Pharmaceuticals Market in US$ Billion, 2013
Figure 6: Breakup of Global Vision Care Industry in US$ Billion, 2013
Figure 7: Global Glaucoma Treatment Market Sales in US$ Billion, 2010-2013
Figure 8: Total Worldwide Glaucoma Market Annual Prescriptions in Million, 2012-2019F
Figure 9: Forecast Global Glaucoma Treatment Market in US$ Billion, 2014F-2019F
Figure 10: Market Share of Commonly Prescribed Glaucoma Drugs in %, 2013
Figure 11: Global Glaucoma Devices Market Size in US$ Million, 2008-2013
Figure 12: Global Glaucoma Devices Market Segmentation in %, 2013
Figure 13: The US Glaucoma Market Sales in US$ Billion, 2012-2020F
Figure 14: The US Glaucoma Market Annual Prescriptions in Million, 2012-2020F
Figure 15: The US Glaucoma Market Composition in %, 2013
Figure 16: The US Prostaglandin Market Sales and Annual Prescriptions, 2012-2020F
Figure 17: The US Beta Blocker Market Sales and Annual Prescriptions, 2012-2020F
Figure 18: The US Combination Glaucoma Market Sales and Annual Prescriptions, 2012-2020F
Figure 19: The US Carbonic Anhydrase Market Sales and Annual Prescriptions, 2012-2020F
Figure 20: Japan Prescription Ophthalmic Pharmaceuticals Market in US$ Billion, 2009-2013
Figure 21: Japan Prescription Ophthalmic Pharmaceuticals Market Segmentation in %, 2013
Figure 22: Japan Glaucoma Treatment Market in US$ Million, 2012-2013
Figure 23: Global Total Population ages 65 and above in Million, 2007-2013
Figure 24: Global Healthcare Expenditures Per Capita in US$, 2007-2013
Figure 25: Share of Monotherapies and Combinations Glaucoma Drugs in %, 2013 versus 2018F
Figure 26: Shares of Global Ophthalmic Laser Market Players in %, 2013
Figure 27: Pfizer's Revenue Share by Business Segments in %, 2013
Figure 28: Pfizer - Revenues from Xalatan/Xalacom in US$ Million, 2011-2013
Figure 29: Merck and Co., Inc. Revenue by Business Segment in %, 2013
Figure 30: Merck and Co., Inc - Revenue from Cosopt/Trusopt in US$ Million, 2011-2013
Figure 31: Allergan Inc Business Segmentation by Revenue in %, 2013
Figure 32: Allergan - Revenue from Total Glaucoma Products in US$ Million, 2011-2013
Figure 33: Revenue from Alcon Division in US$ Million, 2011-2013

List of Tables

Table 1: Commonly Used Glaucoma Medications with Generic Equivalents
Table 2: The US - Xalatan (latanoprost) Estimated Glaucoma Market, 2012-2020F
Table 3: The US - Lumigan (bimatoprost) Estimated Glaucoma Market (AGN), 2012-2020F
Table 4: The US - Travatan (travoprost) Estimated Glaucoma Market, 2012-2020F
Table 5: The US - Zioptan Estimated Glaucoma Market, 2012-2020F
Table 6: The US - Combigan Estimated Glaucoma Market (AGN), 2012-2020F
Table 7: The US - Cosopt Estimated Glaucoma Market (AGN), 2012-2020F
Table 8: The US - Simbrinza Estimated Glaucoma Market (NVS/Alcon), 2013-2020F
Table 9: The US - Carbonic Anhydrase Inhibitors (Branded) Estimated Glaucoma Market, 2012-2020F
Table 10: The US - Carbonic Anhydrase Inhibitors (Generics) Estimated Glaucoma Market, 2012-2020F
Table 11: Alcon - Ophthalmic Projects/Products Planned in Coming Years

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The ophthalmic lasers market is projected to reach USD 1,245.4 million by 2021 from USD 970.2 million in 2016, at a CAGR of 5.1%. Increasing prevalence of ophthalmic disorders, increasing prevalence of ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.